

*Nature Reviews Clinical Oncology* 9, 611 (2012); published online 25 September 2012;  
 doi:10.1038/nrclinonc.2012.177;  
 doi:10.1038/nrclinonc.2012.178;  
 doi:10.1038/nrclinonc.2012.176;  
 doi:10.1038/nrclinonc.2012.179

## IN BRIEF

### HAEMATOLOGICAL CANCER

#### Profiling the molecular phenotype of Hodgkin lymphoma

The pathogenesis of treatment failure in patients with Hodgkin lymphoma (HL) treated with chemotherapy is not well understood. Now, a study has shown that a macrophage-like signature in Hodgkin Reed Sternberg cells from patients with HL significantly correlated with treatment failure. Moreover, expression of the *CSF1R* gene, part of this signature, was significantly associated with progression-free survival and overall survival in 132 patients in an independent validation cohort.

**Original article** Steidl, C. *et al.* Gene expression profiling of microdissected Hodgkin Reed Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. *Blood* doi:10.1182/blood-2012-06-439570

### HAEMATOLOGICAL CANCER

#### TP53 mutations prognostic for DLBCL treated with R-CHOP

The prognostic role of *TP53* mutations in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy is undefined. In a large patient cohort study, those with *TP53* mutations had worse progression-free and overall survival, and mutant *TP53* was predictive of treatment outcome in patients with the germinal centre B-cell and activated B-cell subtypes; underscoring *TP53* stratification potential in these patient subsets.

**Original article** Xu-Monette, Z.Y. *et al.* Mutational profile and prognostic significance of *TP53* in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: a report from an International DLBCL Rituximab-CHOP Consortium Program study. *Blood* doi:10.1182/blood-2012-05-433334

### HAEMATOLOGICAL CANCER

#### Reduced-intensity conditioning preferred for AML

In patients with acute myeloid leukaemia (AML) in first complete remission, reduced-intensity conditioning (RIC) regimens have been developed to minimize toxicity after allogeneic stem cell transplantation. Now, a randomized phase III trial that compared standard conditioning with RIC, showed that nonrelapse mortality, disease-free survival and overall survival were comparable, but grade 3 or 4 oral mucositis was lower with the RIC regimen, indicating that this is the preferred option.

**Original article** Bornhäuser, M. *et al.* Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. *Lancet Oncol.* doi:10.1016/S1470-2045(12)70349-2

### HAEMATOLOGICAL CANCER

#### TAM predict inferior outcome in Hodgkin lymphoma

Tumour-associated macrophages have been linked with a poor outcome in patients with Hodgkin lymphoma. In a multicentre phase III trial of 287 patients randomized to a training cohort and validation cohort, increased expression levels of CD68 and CD163 were significantly associated with worse failure-free and overall survival outcomes in the validation cohort. Analysis of the validation cohort showed both markers were independent predictors of inferior survival outcomes, and thus have prognostic significance.

**Original article** Tan, K. L. *et al.* Tumor-associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: a correlative study from the E2496 Intergroup study. *Blood* doi:10.1182/blood-2012-04-421057